- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00728689
Essai de phase I d'un médicament expérimental contre la variole
Une étude de phase I randomisée, en double aveugle, croisée et exploratoire de la pharmacocinétique d'une dose orale unique de capsules de forme I par rapport à la forme V du composé anti-orthopoxvirus ST-246® chez des volontaires en bonne santé nourris
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.
Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Orlando, Florida, États-Unis, 32809
- Orlando Clinical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18 to 50 years
- Available for clinical follow-up duration of study.
- Able/willing to give written consent.
- Good general health; no clinically significant medical history.
- Refrain from taking any medications from screening through 72 hours after last dose.
- Adequate venous access.
- PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
- Meet Lab Criteria within 28 days prior to receipt of drug.
- Negative pregnancy test
- Non smokers
- No alcohol or caffeine
- Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study
Exclusion Criteria:
-
Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
-
History of additional risk factors for Torsade de Pointes
-
Clinically significant abnormal ECG
-
Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
-
Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
-
History of any clinically significant conditions including:
- Asthma
- Diabetes mellitus
- History of thyroidectomy or thyroid disease
- Serious angioedema episodes
- Head trauma resulting in a diagnosis of TBI other than concussion
- Seizure or history of seizure
- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
- Malignancy
-
Family history of idiopathic seizures
-
History or presence of neutropenia or other blood dyscrasia
-
Known Hepatitis B or Hepatitis C infection
-
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
-
Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
-
Known clinically significant chronic viral infection (or current clinically significant viral infection
-
History of frequent or severe headaches or migraines
-
Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
-
Woman who is pregnant or is breast-feeding or planning to become pregnant
-
On any concomitant medications
-
History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
-
Inability to swallow medication
-
Body Mass Index above 35 or below 18,
-
Current drug abuse or alcohol abuse.
-
Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
-
Clinically significant lactose intolerance
-
Received experimental drug within 30 days
-
Vaccination within 30 days
-
Total of more than 350 milliliters (mL) of blood drawn in 2 months
-
Treatment with any immunosuppressant or immunomodulatory medication in 3 months
-
Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
-
History or diagnosis that would affect absorption of study medication
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Group ST-246 Form I (followed by Form V)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Autres noms:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Autres noms:
|
|
Comparateur actif: Group ST-246 Form V (followed by Form I)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Autres noms:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
Délai: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
Délai: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
Délai: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
Délai: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax) |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
Délai: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
Délai: 4 weeks
|
Evaluated safety parameters included:
|
4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Thomas C Marbury, MD, Orlando Clinical Research Center
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SIGA-246-005
- HHSN266200600014C (Autre subvention/numéro de financement: NIAID)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .